The Evolutio
The Evolution of Spatial Biology Companies in 2025
In the ever-evolving landscape of biotechnology, spatial biology has emerged as a pivotal field, transforming drug discovery and biomedical research. By 2025, companies leading this charge have seen significant growth in revenues, capital investments, and innovative activities, underscoring the field’s burgeoning importance.
At the forefront of this movement is LatchBio, a San Francisco-based startup that recently unveiled an impressive 25-million-cell atlas for spatial transcriptomics. This open-source resource covers 45 tissue types, 63 diseases, and 11 spatial technologies, marking it as the largest human spatial atlas to date. Such advancements are not confined to startups; pharmaceutical giants like GlaxoSmithKline (GSK) have also embraced spatial biology. GSK collaborates with Relation Therapeutics, utilizing its Lab-in-the-Loop platform which integrates spatial and single-cell transcriptomics with other multi-modal patient data. This partnership aims to accelerate target identification for conditions such as fibrotic diseases and osteoarthritis.
Andrew Farmer, DPhil, chief scientific officer at Takara Bio USA, eloquently defines spatial biology’s essence: it is not merely about identifying cell types within tissues but understanding their precise locations, interactions, and communications. Takara Bio itself made waves by acquiring Curio Bioscience, a spatial genomics company. This acquisition highlights the strategic importance companies place on expanding into spatial biology to stay competitive.
Financial metrics reveal robust growth among leading firms in this domain. The top five public companies have experienced a 9% increase in revenues for the first half of 2025 compared to the previous year, although this represents a slowdown from the rapid 21% revenue jump recorded in 2024. Similarly, private sector players saw an 8% rise in capital raised, indicating sustained investor confidence.
Leading the public companies is Bruker, with its Nano segment, including spatial biology, generating significant revenues through innovative technologies unveiled at the American Association for Cancer Research meeting. These include the CosMx WTX assay and other advanced platforms that enhance subcellular imaging and proteomics analysis.
10x Genomics and Bio-Techne follow closely, each expanding their spatial biology portfolios with new technologies and strategic partnerships, despite recent workforce reductions and legal settlements in 10x’s case. Standard BioTools and Quanterix also continue to refine their offerings in the spatial biology space, leveraging acquisitions and integrations to broaden their market reach.
In the private sector, Vizgen stands out for its MERSCOPE® platform, which has garnered attention through significant research publications. Resolve Biosciences, RareCyte, Stellaromics, and Nucleai also contribute innovative tools and platforms that enrich spatial biology applications in research and clinical settings.
As we look to 2025, the trajectory of these companies reflects a broader trend towards precision medicine and personalized healthcare solutions. The growth in spatial biology is not just about technological advancements but a paradigm shift towards understanding biological systems at an unprecedented level of detail. This transformative journey promises to unlock new possibilities in diagnosing and treating diseases, fundamentally altering how we approach health and wellness.
For more insights into the top movers in spatial biology, explore additional resources and engage with industry leaders who are shaping this dynamic field.
For further reading and updates on this topic, consider subscribing to GEN’s digital editions and newsletters.